Suzano (SUZB3) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
18 Jan, 2026Executive summary
Sales volumes and EBITDA increased, driven by a well-defined commercial strategy, favorable FX, and strong Ribas do Rio Pardo Unit performance, despite higher cash costs and challenging Chinese pulp market conditions.
The Ribas mill ramp-up exceeded efficiency expectations, marking the peak of higher costs as past, with further improvements anticipated.
Largest investment cycle completed, enabling a new phase of competitiveness and cash generation.
Leverage continued its planned decline, reaching 3.1x net debt/EBITDA, with net debt in USD at $12.9 billion.
Strategic acquisitions in forestry assets, Lenzing, and Suzano Packaging US support business strategy and value extraction.
Financial highlights
Adjusted EBITDA reached R$6.5 billion, up 4% sequentially and 77% year-over-year, with margin at 53%.
Net revenue was R$12.3 billion, up 7% from 2Q24 and 37% year-over-year, with 79% from exports.
Operating cash generation was R$4.4 billion, and net income was R$3.2 billion, reversing a loss in 2Q24.
Net debt rose to $12.9 billion due to asset acquisitions and share buybacks, but leverage ratio improved to 3.1x.
Paper and packaging EBITDA decreased 8% year-over-year due to lower prices, despite higher sales volumes.
Outlook and guidance
Focus remains on value generation from new assets, Cerrado Project delivery, and continued deleveraging.
Ribas do Rio Pardo Unit ramp-up on track, targeting 900k tons in 2024 and 2.0 million tons by 12 months of operation.
2025 CapEx to be lower, with further cash cost reductions anticipated as Ribas ramps up.
Logistics costs to remain high due to ongoing disruptions, but cash costs expected to improve in Q4 with no major maintenance stoppages.
Enhanced resilience expected in all price scenarios following investment cycle completion.
Latest events from Suzano
- Record sales, cost discipline, and strong liquidity support a positive outlook.SUZB3
Q4 202511 Feb 2026 - EBITDA up 60% year-over-year, but net loss of R$3.77B on FX and derivative impacts.SUZB3
Q2 20241 Feb 2026 - Cost leadership, operational excellence, and disciplined capital allocation drive growth.SUZB3
Investor Day 202411 Jan 2026 - Record sales and EBITDA driven by Ribas ramp-up, but FX losses led to a net loss.SUZB3
Q4 20248 Jan 2026 - Focus is on competitiveness, cost reduction, and disciplined growth amid market shifts.SUZB3
Investor Day 202512 Dec 2025 - Strong sales growth, robust cash flow, and major strategic moves marked the quarter.SUZB3
Q2 202523 Nov 2025 - Net income rose to R$6.3B in 1Q25, with stable leverage and strong free cash flow.SUZB3
Q1 202518 Nov 2025 - JV creates a global tissue leader with $3.3bn revenue, $175M synergies, and strong diversification.SUZB3
Investor Update12 Nov 2025 - Cash cost below BRL 800/ton, EBITDA down 20%, leverage up, 2025 capex guidance reaffirmed.SUZB3
Q3 20257 Nov 2025